Skip to search formSkip to main contentSkip to account menu

PK1 doxorubicin-HPMA conjugate

Known as: PK1 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (3)

DoxorubicinPolymethacrylic Acidsdoxorubicin-HPMA conjugate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2009
Highly Cited
2009
Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer.
Phase I studies of [N-(2-hydroxypropyl)methacrylamide] (HPMA) copolymer-doxorubicin previously showed signs of activity coupled… 
Highly Cited
2006
Highly Cited
2006
Gentamicin Causes Apoptosis at Low Concentrations in Renal LLC-PK1 Cells Subjected to Electroporation
ABSTRACT Gentamicin accumulates in the lysosomes of kidney proximal tubular cells and causes apoptosis at clinically relevant… 
Highly Cited
2004
Highly Cited
2004
Expression and regulation of the prokineticins (endocrine gland-derived vascular endothelial growth factor and Bv8) and their receptors in the human endometrium across the menstrual cycle.
This study investigated the possible role of the newly discovered endocrine gland-derived vascular endothelial growth factors and… 
Highly Cited
2001
Highly Cited
2001
Polymer-drug conjugates, PDEPT and PELT: basic principles for design and transfer from the laboratory to clinic.
Highly Cited
2001
Highly Cited
2001
Cellular overexpression of heme oxygenase-1 up-regulates p21 and confers resistance to apoptosis.
BACKGROUND Induction of heme oxygenase-1 (HO-1) protects against diverse insults in the kidney and other tissues. We examined the… 
Highly Cited
2000
Highly Cited
2000
Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells.
Human pancreatic adenocarcinoma cell lines PK1 and PK8 are resistant to the clinically relevant chemotherapy agent gemcitabine… 
Highly Cited
1999
Highly Cited
1999
Phase I Clinical and Pharmacokinetic Study of PK1 [N-(2-Hydroxypropyl)methacrylamide Copolymer Doxorubicin]: First Member of a New Class of Chemotherapeutic Agents—Drug-Polymer Conjugates
PK1 comprises doxorubicin covalently bound to N -(2-hydroxypropyl)methacrylamide copolymer by a peptidyl linker. Following… 
Highly Cited
1999
Highly Cited
1999
Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer…
PK1 comprises doxorubicin covalently bound to N-(2-hydroxypropyl)methacrylamide copolymer by a peptidyl linker. Following… 
Highly Cited
1994
Highly Cited
1994
In vivo properties of SB 200646A, a 5‐HT2C/2B receptor antagonist
1 SB 200646A, N‐(1‐methyl‐5‐indolyl)‐N′‐(3‐pyridyl) urea hydrochloride, the first reported selective 5‐HT2C/2B over 5‐HT2A… 
Highly Cited
1985
Highly Cited
1985
Biochemical characterization of renal epithelial cell cultures (LLC-PK1 and MDCK).
The expression of enzymes in LLC-PK1 and MDCK cells was used to study the retention of differentiated properties of the renal… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)